Cargando…
Serial KL-6 measurements in COVID-19 patients
SARS-CoV2-induced direct cytopathic effects against type II pneumocytes are suspected to play a role in mediating and perpetuating lung damage. The aim of this study was to evaluate serum KL-6 behavior in COVID-19 patients to investigate its potential role in predicting clinical course. Sixty patien...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811154/ https://www.ncbi.nlm.nih.gov/pubmed/33453011 http://dx.doi.org/10.1007/s11739-020-02614-7 |
_version_ | 1783637442920710144 |
---|---|
author | d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Curatola, Giuseppe Remediani, Lorenzo Bennett, David Bianchi, Francesco Perillo, Felice Volterrani, Luca Mazzei, Maria Antonietta Bargagli, Elena |
author_facet | d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Curatola, Giuseppe Remediani, Lorenzo Bennett, David Bianchi, Francesco Perillo, Felice Volterrani, Luca Mazzei, Maria Antonietta Bargagli, Elena |
author_sort | d’Alessandro, Miriana |
collection | PubMed |
description | SARS-CoV2-induced direct cytopathic effects against type II pneumocytes are suspected to play a role in mediating and perpetuating lung damage. The aim of this study was to evaluate serum KL-6 behavior in COVID-19 patients to investigate its potential role in predicting clinical course. Sixty patients (median age IQR, 65 (52–69), 43 males), hospitalized for COVID-19 at Siena COVID Unit University Hospital, were prospectively enrolled. Twenty-six patients were selected (median age IQR, 63 (55–71), 16 males); all of them underwent follow-up evaluations, including clinical, radiological, functional, and serum KL-6 assessments, after 6 (t1) and 9 (t2) months from hospital discharge. At t0, KL-6 concentrations were significantly higher than those at t1 (760 (311–1218) vs. 309 (210–408) p = 0.0208) and t2 (760 (311–1218) vs 324 (279–458), p = 0.0365). At t0, KL-6 concentrations were increased in patients with fibrotic lung alterations than in non-fibrotic group (755 (370–1023) vs. 305 (225–608), p = 0.0225). Area under the receiver operating curve (AUROC) analysis showed that basal KL-6 levels showed good accuracy in discriminating patients with fibrotic sequelae radiologically documented (AUC 85%, p = 0.0404). KL-6 concentrations in patients with fibrotic involvement were significantly reduced at t1 (755 (370–1023) vs. 290 (197–521), p = 0.0366) and t2 (755 (370–1023) vs. 318 (173–435), p = 0.0490). Serum concentrations of KL-6 in hospitalized COVID-19 patients may contribute to identify severe patients requiring mechanical ventilation and to predict those who will develop pulmonary fibrotic sequelae in the follow-up. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-020-02614-7. |
format | Online Article Text |
id | pubmed-7811154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-78111542021-01-18 Serial KL-6 measurements in COVID-19 patients d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Curatola, Giuseppe Remediani, Lorenzo Bennett, David Bianchi, Francesco Perillo, Felice Volterrani, Luca Mazzei, Maria Antonietta Bargagli, Elena Intern Emerg Med Im - Original SARS-CoV2-induced direct cytopathic effects against type II pneumocytes are suspected to play a role in mediating and perpetuating lung damage. The aim of this study was to evaluate serum KL-6 behavior in COVID-19 patients to investigate its potential role in predicting clinical course. Sixty patients (median age IQR, 65 (52–69), 43 males), hospitalized for COVID-19 at Siena COVID Unit University Hospital, were prospectively enrolled. Twenty-six patients were selected (median age IQR, 63 (55–71), 16 males); all of them underwent follow-up evaluations, including clinical, radiological, functional, and serum KL-6 assessments, after 6 (t1) and 9 (t2) months from hospital discharge. At t0, KL-6 concentrations were significantly higher than those at t1 (760 (311–1218) vs. 309 (210–408) p = 0.0208) and t2 (760 (311–1218) vs 324 (279–458), p = 0.0365). At t0, KL-6 concentrations were increased in patients with fibrotic lung alterations than in non-fibrotic group (755 (370–1023) vs. 305 (225–608), p = 0.0225). Area under the receiver operating curve (AUROC) analysis showed that basal KL-6 levels showed good accuracy in discriminating patients with fibrotic sequelae radiologically documented (AUC 85%, p = 0.0404). KL-6 concentrations in patients with fibrotic involvement were significantly reduced at t1 (755 (370–1023) vs. 290 (197–521), p = 0.0366) and t2 (755 (370–1023) vs. 318 (173–435), p = 0.0490). Serum concentrations of KL-6 in hospitalized COVID-19 patients may contribute to identify severe patients requiring mechanical ventilation and to predict those who will develop pulmonary fibrotic sequelae in the follow-up. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-020-02614-7. Springer International Publishing 2021-01-16 2021 /pmc/articles/PMC7811154/ /pubmed/33453011 http://dx.doi.org/10.1007/s11739-020-02614-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Im - Original d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Curatola, Giuseppe Remediani, Lorenzo Bennett, David Bianchi, Francesco Perillo, Felice Volterrani, Luca Mazzei, Maria Antonietta Bargagli, Elena Serial KL-6 measurements in COVID-19 patients |
title | Serial KL-6 measurements in COVID-19 patients |
title_full | Serial KL-6 measurements in COVID-19 patients |
title_fullStr | Serial KL-6 measurements in COVID-19 patients |
title_full_unstemmed | Serial KL-6 measurements in COVID-19 patients |
title_short | Serial KL-6 measurements in COVID-19 patients |
title_sort | serial kl-6 measurements in covid-19 patients |
topic | Im - Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811154/ https://www.ncbi.nlm.nih.gov/pubmed/33453011 http://dx.doi.org/10.1007/s11739-020-02614-7 |
work_keys_str_mv | AT dalessandromiriana serialkl6measurementsincovid19patients AT bergantinilaura serialkl6measurementsincovid19patients AT camelipaolo serialkl6measurementsincovid19patients AT curatolagiuseppe serialkl6measurementsincovid19patients AT remedianilorenzo serialkl6measurementsincovid19patients AT bennettdavid serialkl6measurementsincovid19patients AT bianchifrancesco serialkl6measurementsincovid19patients AT perillofelice serialkl6measurementsincovid19patients AT volterraniluca serialkl6measurementsincovid19patients AT mazzeimariaantonietta serialkl6measurementsincovid19patients AT bargaglielena serialkl6measurementsincovid19patients AT serialkl6measurementsincovid19patients |